Scholarlink

Background <p><i>Serratia marcescens</i> is an opportunistic pathogen increasingly associated with healthcare-associated infections and rising antimicrobial resistance. The emergence of multidrug-resistant (MDR) and carbapenem-resistant <i>S. marcescens</i> (CRSM) presents significant therapeutic challenges. However, data on the clinical and microbiological analyses of these infections remain limited.</p> Methods <p>This retrospective study included 242 hospitalized patients with <i>S. marcescens</i> infections admitted to Nanjing Drum Tower Hospital, China, from January 2012 to December 2020. Clinical characteristics, antimicrobial susceptibility profiles, and resistance patterns were analyzed. Patients were categorized based on infection site (urinary tract infection [UTI] vs. bloodstream infection [BSI]) and resistance phenotype (MDR and CRSM). Antimicrobial susceptibility testing (AST) was performed according to CLSI 2024 guidelines. Univariate and multivariate logistic regression analyses were conducted to identify independent risk factors associated with BSI, UTI, and CRSM.</p> Results <p>MDR isolates exhibited significantly lower susceptibility to β-lactams, aminoglycosides, and fluoroquinolones compared to non-MDR isolates, although amikacin and sulfamethoxazole retained moderate activity. Isolates from blood samples showed higher susceptibility to most antibiotics than urinary isolates, particularly imipenem (23.5% vs. 3.2%). Multivariate analysis identified prior hospitalization as an independent risk factor for <i>S. marcescens</i> BSI (OR = 2.8, <i>P</i> = 0.048), while kidney disease (OR = 4.2, <i>P</i> &lt; 0.001) was independently associated with UTIs. Pulmonary infection (OR = 3.2, <i>P</i> = 0.020) and prior exposure to ≥ 3 antibiotic classes (OR = 3.7, <i>P</i> = 0.031) were independent predictors of carbapenem-resistant infections. Patients with MDR bacteremia had a markedly higher 28-day mortality (50.0%) than non-MDR cases (12.0%). The 28-day mortality rate for CRSM infections was 28.6%.</p> Conclusion <p>This study reveals substantial differences in antimicrobial susceptibility between MDR and non-MDR <i>S. marcescens</i> isolates and highlights amikacin and sulfamethoxazole as potential treatment options against MDR strains. Didentified clinical risk factors—including prior hospitalization, kidney disease, and extensive antibiotic exposure—underscore the importance of early risk stratification and optimized antibiotic stewardship.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Epidemiology, resistance profiles, and risk factors of multidrug- and carbapenem-resistant Serratia marcescens infections: a retrospective study of 242 cases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月9日

查看全文
  • Hong Zhu,
  • Fengyan Li,
  • Xiaoli Cao,
  • Yan Zhang,
  • Chang Liu,
  • Yuxin Chen,
  • Han Shen

摘要

Background

Serratia marcescens is an opportunistic pathogen increasingly associated with healthcare-associated infections and rising antimicrobial resistance. The emergence of multidrug-resistant (MDR) and carbapenem-resistant S. marcescens (CRSM) presents significant therapeutic challenges. However, data on the clinical and microbiological analyses of these infections remain limited.

Methods

This retrospective study included 242 hospitalized patients with S. marcescens infections admitted to Nanjing Drum Tower Hospital, China, from January 2012 to December 2020. Clinical characteristics, antimicrobial susceptibility profiles, and resistance patterns were analyzed. Patients were categorized based on infection site (urinary tract infection [UTI] vs. bloodstream infection [BSI]) and resistance phenotype (MDR and CRSM). Antimicrobial susceptibility testing (AST) was performed according to CLSI 2024 guidelines. Univariate and multivariate logistic regression analyses were conducted to identify independent risk factors associated with BSI, UTI, and CRSM.

Results

MDR isolates exhibited significantly lower susceptibility to β-lactams, aminoglycosides, and fluoroquinolones compared to non-MDR isolates, although amikacin and sulfamethoxazole retained moderate activity. Isolates from blood samples showed higher susceptibility to most antibiotics than urinary isolates, particularly imipenem (23.5% vs. 3.2%). Multivariate analysis identified prior hospitalization as an independent risk factor for S. marcescens BSI (OR = 2.8, P = 0.048), while kidney disease (OR = 4.2, P < 0.001) was independently associated with UTIs. Pulmonary infection (OR = 3.2, P = 0.020) and prior exposure to ≥ 3 antibiotic classes (OR = 3.7, P = 0.031) were independent predictors of carbapenem-resistant infections. Patients with MDR bacteremia had a markedly higher 28-day mortality (50.0%) than non-MDR cases (12.0%). The 28-day mortality rate for CRSM infections was 28.6%.

Conclusion

This study reveals substantial differences in antimicrobial susceptibility between MDR and non-MDR S. marcescens isolates and highlights amikacin and sulfamethoxazole as potential treatment options against MDR strains. Didentified clinical risk factors—including prior hospitalization, kidney disease, and extensive antibiotic exposure—underscore the importance of early risk stratification and optimized antibiotic stewardship.